Aim: While electroconvulsive therapy (ECT) is a well-established, safe, and effective treatment for mental illnesses, the potential for adverse effects on cognitive functions remains controversial. We aimed to evaluate multiple cognitive functions in different time periods before and after ECT in a Japanese population.
Aim: While electroconvulsive therapy (ECT) is a well-established, safe, and effective treatment for mental illnesses, the potential for adverse effects on cognitive functions remains controversial. We aimed to evaluate multiple cognitive functions in different time periods before and after ECT in a Japanese population.
Methods: A battery of five neurocognitive tests was administered to patients who underwent a course of ECT treatment at three time points: before, immediately after, and 4 weeks after ECT.
Results: A transient but significant decline in letter fluency function was observed immediately after ECT, but had recovered well by 4 weeks. We also observed a significant improvement in the trailmaking task at 4 weeks after ECT.
Conclusion:
In a Japanese population, adverse effects of ECT on verbal fluency function-related and other cognitive impairments were transient. Over the longer term, we detected significant improvements in the performance of tasks that presumably reflected information processing speed and executive functions.
Key words: cognitive function, depression, electroconvulsive therapy, information processing speed, verbal fluency. E LECTROCONVULSIVE THERAPY (ECT) is a safe, effective treatment for severe psychiatric illnesses, particularly depression. [1] [2] [3] Although the mortality rate with ECT is extremely low, 4-7 some adverse effects are of concern (headache, hypertension, short-term cognitive effects, etc.). Among these, prolonged cognitive impairment represents one of the most undesirable adverse effects, and would limit ECT use. 8, 9 The cognitive effects of ECT can be divided into several dimensions: memory function (encoding, storage, and retrieval); attention; orientation; and executive function. Although the long-term cognitive side-effects of ECT have been believed to be not subtle, some groups of researchers have concluded that cognitive deficits after ECT are limited to the short term or are tolerable even in systematic reviews or meta-analyses based largely on data from elderly individuals with mood disorders. [10] [11] [12] They concluded that most types of cognitive function are not severely impaired by ECT, even among elderly people whose cognitive functions are of more concern than those of younger populations. Other research groups, however, have observed significant autobiographical memory loss or retrograde amnesia after ECT. 9, 13, 14 Given such inconsistencies, it is crucial to monitor overall cognitive functions in different time periods before and after ECT under relatively homogeneous conditions and backgrounds to evaluate the cognitive effectiveness and efficacy of ECT. We therefore conducted this study to elucidate whether ECT has effects on cognition and what form any such effects take. The study was designed to use cognitive tests to objectively cover a broad range of cognitive functions in a Japanese population, and to cover a sufficiently long period, from before to 4 weeks after ECT.
METHODS Subjects
The study population consisted of consecutive inpatients who underwent ECT from April 2003 to March 2012 in the psychiatric ward at Tokyo Medical and Dental University Medical Hospital. Only patients who could receive the cognitive battery before the ECT course and at least once after the ECT course were included; indeed, only subjects who completed cognitive test batteries at all three time points were included in the analysis. Data from the most recent ECT treatment course were used for those patients who received more than two separate courses of ECT treatment during the study period.
Ethics
All study protocols were approved by the ethics committee of Tokyo Medical and Dental University Medical Hospital. All subjects provided written informed consent for cognitive tests, ECT, and anesthetic treatments. In strict accordance with the Declaration of Helsinki, the decision to conduct ECT was made by the experts in agreement with the free will of the patient and/or their family, completely independently from study participation.
ECT treatment
Patients were usually given ECT twice a week in an operating room under the physical control of an anesthesiologist. An ECT apparatus (Thymatron System IV, Somatics; LLC, Lake Bluff, IL, USA) containing a built-in electroencephalographic (EEG) recording system (Fp1-A1, Fp2-A2, international 10-20 system) was used for pulse wave stimulation with a pulse width of 0.5 ms and a pulse frequency of 70 Hz. Seizure duration was monitored by EEG and the isolated limb method. The total number of treatment sessions was adjusted by the physicians, up to 12 sessions per treatment course, in view of symptomatic recovery. Propofol (1.0-1.5 mg/kg, intravenous) and succinylcholine (20-40 mg, intravenous) were used for anesthesia. The first stimulation dosage was calculated using the half-age method. 15, 16 After the first stimulation, the stimulation dosage was titrated based on seizure duration and clinical judgment. The stimulation dosage was increased by 1.5-fold from the previous ECT session if the seizure was shorter than 25 s on the EEG. The amplitude and coherence of seizures on EEG, postictal suppression, heart rate on electrocardiogram, and blood pressure were also monitored to be included in clinical judgment. If no seizure was induced, restimulation was employed in the same ECT session. All ECT stimulations were applied using bilateral fronto-temporal electrode placement. 17 
Neurocognitive assessment
We applied a battery of cognitive tests at three time points: (i) pre-ECT; (ii) early post-ECT; and (iii) late (4 weeks) post-ECT. The cognitive tests before ECT (Pre-ECT) were administered within 4 days before the session of first ECT. Cognitive tests immediately after ECT (Post-ECT) were administered within 4 days after the last ECT session. Cognitive tests 4 weeks after ECT (4 W after ECT) were administered in the fourth week after the last ECT session. Cognitive tests consisted of the Mini-Mental State Examination (MMSE), 18 the Rivermead Behavioral Memory Test (RBMT), 19 the Trail-Making Test B (TMT-B), 20 the Thurstone Word Fluency Test (TWFT, a category fluency task), 21 and the Controlled Oral Word Association (COWA) test (a letter fluency task). 22 To circumvent possible learning effects with repeat performances, some objects used in memory tasks in the RBMT were changed in each time.
Statistical analysis
For multiple comparisons of matched data, we used the Friedman test followed by Dunn's post-hoc test. We used the Mann-Whitney U-test for comparisons of unpaired data, and the Wilcoxon signed-ranks test for comparisons of paired data. To examine correlations between cognitive tests, we used Spearman's rank correlation test. Analyses were performed using PRISM 6 software (GraphPad Software, La Jolla, CA, USA).
RESULTS

Profiles of the participants
From April 2003 to March 2012, a total of 214 patients were treated with ECT in our hospital. Among these, 100 patients (39 men, 61 women; mean age, 52.6 years; range, 19-81 years) consented to participate in the study and were enrolled to receive the Pre-ECT cognitive test battery. The other 114 patients were not included because consent was not obtained, symptoms were too severe to tolerate the cognitive test battery, or they could not be scheduled to receive the cognitive battery after ECT. Diagnoses based on interviews with board-certified Japanese psychiatrists and according to DSM-IV criteria were as follows: major depressive disorder, 91 patients; and schizophrenia, nine patients. Eighty-three patients (37 men, 46 women; mean age, 52.3 years; range, 19-81 years; major depressive disorder, n = 78; schizophrenia, n = 5) received the cognitive assessment battery at pre-ECT, while the remaining 17 patients could not receive the cognitive tests at Pre-ECT assessment because of inadvertent errors or intolerance. The flow of potential patients through this study is summarized in Figure 1 . Detailed demographic data, including sex, age, diagnosis, ECT dosage, ECT treatment frequency, results of cognitive tests at Pre-ECT, and psychotropic drug information, are shown in Table S1 . As seen in Table S1 , ECT had a moderate to marked beneficial effect and all patients showed a higher Global Assessment of Functioning score at discharge from hospital than on admission. Of the 83 patients analyzed Pre-ECT, the re-evaluation battery was administered immediately after ECT (Post-ECT) for 68 patients, and 4 weeks after (4 W after ECT) for 38 patients. Fifteen patients could not complete both Post-ECT and 4 W after ECT assessments because they left our hospital before assessment completion, or refused continuation of the assessments, and 33 patients were lost to follow up at 4 W after ECT because of inadvertent errors or scheduling problems. Three patients performed assessments at 4 W after ECT without completing the Post-ECT assessments. Overall, 35 patients completed the evaluations at all three time points. Mean and standard errors of scores for cognitive tests at Pre-ECT for these 35 patients are shown in Table 1 
Time course of cognitive declines and improvements after ECT
The results for five outcome measures of cognitive function at the three time points in the 35 patients who completed assessments at all three time points around ECT are summarized in Table 1 vs Pre-ECT: P < 0.05, Friedman test after Dunn's multiple comparison test). At 4 weeks, but not immediately after ECT, we found a significant improvement in TMT-B results (4 W after ECT vs Pre-ECT: P < 0.01; 4 W after ECT vs Post-ECT: P < 0.001). In other measurements, although we did not observe any significant differences in cognitive function between the three time points, pair-wise comparisons of two time points with a larger number of patients (n = 68) who underwent both pre-ECT and post-ECT assessments revealed a significant decline in RBMT scores, verbal fluency testing for animal names, and letter fluency (Table S2 ). Average cognitive test scores for these 68 subjects at pre-ECT were: MMSE, 27.34; RBMT, 19.28; TMT-B, 198.04; TWFT, 16.65; and COWA, 11.36. We confirmed that these functions had recovered well by 4 W after ECT, and detected further significant improvements in TMT-B scores in pair-wise comparisons of the Pre-ECT and 4 W after ECT time points (n = 38, Table S3 ). Average scores for these 38 subjects at pre-ECT were: MMSE, 27 
Correlation of cognitive changes among the five assessments
Next, we examined correlations among the changes of these five cognitive function measurements between Pre-and Post-ECT. MMSE and RBMT scores (P < 0.001, Spearman's rank correlation test) and TMT-B and COWA scores (P < 0.001, Spearman's rank correlation test) showed significant correlations in the changes of corresponding scores between Preand Post-ECT (Table 2) in 35 patients. We observed significant correlations in MMSE and RBMT (Table 3) . We observed similar significant correlations in pair-wise comparisons at two time points (changes of cognitive values Post-vs Pre-ECT: correlations between MMSE and TMT-B, P < 0.001; MMSE and RBMT, P < 0.01; TMT-B and COWA, P < 0.05 as shown in Table S4 , and changes in cognitive values 4 W after vs Pre-ECT: correlations between MMSE and RBMT, P < 0.01; TWFT and COWA, P < 0.05 as shown in Table S5 ).
DISCUSSION
The importance of adverse effects of ECT in terms of cognitive function remains controversial. Some studies have reported that ECT induces prolonged retrograde amnesia. 23, 24 Persistent retrograde amnesia induced during ECT has been hypothesized to be due to saturation of long-term synaptic changes or long-term potentiation. 25 On the other hand, another study found no significant difference in cognitive functioning at the end of the course of ECT between patients treated with ECT and those treated with pharmacotherapy. 1 To clarify this inconsistency, we aimed at evaluating multi-dimensional cognitive functions in different time periods before and after ECT in a Japanese population.
First, three-point evaluation revealed a transient adverse effect immediately after ECT on the letter fluency test. This decline in COWA scores (letter fluency) correlated significantly with that of TMT-B. Furthermore, two-point evaluation with a larger sample detected significant declines in RBMT, TWFT (animal naming category fluency), and COWA immediately after ECT. RBMT is useful to evaluate memory impairments related to daily activities. 26 Our data thus suggested that multi-dimensional neurocognitive functions, including daily memory performance, show transient declines just after ECT when compared with before ECT.
Second, we observed significant improvements to TMT-B score at 4 weeks after ECT when compared with before ECT, without any significant correlation with other cognitive tests. TMT-B is thought to reflect both information processing speed and executive function, including set-shifting abilities. This suggests that these kinds of neurocognitive improvements observed may predominate for some time after ECT, even when some of these neurocognitive improvements are related to overall improvement of the mental state of the patients by ECT treatment.
Third, MMSE and RBMT scores showed significant correlations in the changes of corresponding scores between Pre-and Post-ECT and between Pre-and 4 W after ECT with a small P-value. Both tests evaluate a broad range of cognitive functions, including memory, and RBMT significantly declined soon after ECT as noted above and MMSE did not decline. Therefore RBMT seems to be the better screening test than MMSE to detect subtle cognitive declines after ECT.
Fourth, TMT-B and COWA scores showed significant correlations in the changes of corresponding scores between Pre-and Post-ECT. TMT-B is thought to reflect information processing speed. The letter fluency that is evaluated by COWA is thought to be affected by processing speed. The correlation between TMT-B and COWA might be due to this common factor. In a recent meta-analysis based on a review of 24 neurocognitive variables from 84 studies, Semkovska and McLoughlin reported that significant decreases in cognitive performance were limited to the first 3 days post-ECT, and processing speed, working memory, anterograde memory, and other executive functions were all improved beyond baseline levels after 15 days. 10 Although the reviewed articles were heterogeneous in terms of diagnostic processes, conditions of ECT treatment, and neurocognitive evaluations, several characteristic outcomes were extracted: (i) small to large subacute impairment in verbal memory relative to baseline, although subacute outcomes in memory, overall global cognition (MMSE), and processing speed (TMT-A) were heterogeneous; (ii) bitemporal ECT was associated with significantly greater improvement in MMSE (medium effect size) from baseline than unilateral ECT at short-term follow-up, and was also associated with improved digit span backward (medium effect size) in the long-term; and (iii) as a long-term outcome, small improvements in processing speed relative to baseline were observed in executive functions, that is, small to medium improvements, or baseline levels, were observed at long-term reassessments. Our present findings in a Japanese population are broadly consistent with those observations. Studies of the neurocognitive effects of ECT in Japanese populations seem to be limited to two reports from one research group with small numbers of samples (eight patients in Azuma et al. 27 and 18 patients with either pulse wave or sine wave stimulation in Fujita et al.
28
). They observed improvement of neurocognitive functions at 2 weeks after ECT, 27 and found no significant difference in cognitive effects between sine wave and pulse wave. 28 Our results showed only transient cognitive deficit after ECT, with no permanent changes. This result is another piece of evidence for the safety of ECT. We conclude that effects on cognition do not represent any obstruction to employing ECT. Based on more recent observations, other researchers have concluded that autobiographical memory loss or retrograde amnesia as long-term cognitive side-effects of ECT represent the most critical adverse effects, with either subtle or no deficits in other dimensions. 29 In this regard, it is crucial to further evaluate cognitive functions during courses of ECT in high-quality studies with larger sample sizes to clarify clinical outcomes.
One key limitation was that detailed measurement of symptoms could not be performed. The severity of depression can cause neurocognitive declines as a part of symptoms, such as psychomotor retardation. This neurocognitive decline can recover along with the symptom relief achieved by treatment, 30 unlike the cognitive deficits associated with schizophrenia, which are basically permanent. 31 Most of our participants were suffering from depression and seemed to achieve significant improvement of depressive symptoms after ECT because they showed apparent improvements in Global Assessment of Functioning. The neurocognitive improvement seen at 4 weeks after ECT in this study thus may have been partly explained by achieving relief from symptoms of depression. However, the deficits on neuropsychological testing in depression demonstrated in many previous studies show moderate effect sizes in broad neurocognitive domains, such as processing speed, attention, executive function, learning, and memory. 32 If our results were mostly attributable to this effect, most of the cognitive tests should have shown moderate improvement. Instead, our results showed neurocognitive improvement only in TMT-B and a size effect that was more than moderate. We therefore believe that our results are mainly explainable by the effects of ECT.
Another limitation was the high dropout rate in this study. Only 35 of the 100 potential patients completed assessments at all three time points. This high dropout rate was attributed to the study design. Many of our participants were patients referred from other medical institutes, psychiatric clinics, or psychiatric hospitals. These patients were sent back to the referring institutes for follow-up after ECT, and continuous cognitive assessment at our institute was thus not feasible. Scheduling cognitive tests after ECT was difficult, especially 4 weeks after ECT. Future studies need to be designed in consideration of such dropouts. However, collecting patients would have been more difficult if this type of patient had been ruled out.
In conclusion, we evaluated the neurocognitive effects of ECT in a Japanese population for both the short and long term. The adverse effects of ECT on verbal fluency-related and other cognitive impairments occurred in a transient manner. Over the longer term after ECT, we detected significant neurocognitive improvements in information processing speed and executive function.
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